title: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
abstract: The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. cwillett@partners.org
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Willett
authors.forename: Yves
authors.initials: Y
authors.lastname: Boucher
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: di Tomaso
authors.forename: Dan G
authors.initials: DG
authors.lastname: Duda
authors.forename: Lance L
authors.initials: LL
authors.lastname: Munn
authors.forename: Ricky T
authors.initials: RT
authors.lastname: Tong
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Chung
authors.forename: Dushyant V
authors.initials: DV
authors.lastname: Sahani
authors.forename: Sanjeeva P
authors.initials: SP
authors.lastname: Kalva
authors.forename: Sergey V
authors.initials: SV
authors.lastname: Kozin
authors.forename: Mari
authors.initials: M
authors.lastname: Mino
authors.forename: Kenneth S
authors.initials: KS
authors.lastname: Cohen
authors.forename: David T
authors.initials: DT
authors.lastname: Scadden
authors.forename: Alan C
authors.initials: AC
authors.lastname: Hartford
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Fischman
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Clark
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
authors.forename: Andrew X
authors.initials: AX
authors.lastname: Zhu
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Blaszkowsky
authors.forename: Helen X
authors.initials: HX
authors.lastname: Chen
authors.forename: Paul C
authors.initials: PC
authors.lastname: Shellito
authors.forename: Gregory Y
authors.initials: GY
authors.lastname: Lauwers
authors.forename: Rakesh K
authors.initials: RK
authors.lastname: Jain
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D020533:Angiogenesis Inhibitors / Q000378:metabolism* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000378:metabolism* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab